This company’s war chest is overlooked by most

Sponsored By Hey, trader - Jeff Bishop here, If you’ve been following our updates for Synaptogenix[(]([SNPX]([)](, you know we’re not only big fans of what the company is striving to achieve in its fight against Alzheimer’s disease, but also the fundamentals of this company.  I’m talking about [SNPX’](s financial health – which is paramount to seeing a biotech through the long stretches of the FDA approval process.  [SNPX]( is in a strong financial position to run this race in its fight against Alzheimer’s.  If you go back to the company’s roots, you will see its foundation is built on technology that has been developed over a DECADE through funding of over $200M from the Blanchette Rockefeller Neurosciences Institute and the National Institutes of Health (NIH) -- Yep, those Rockefeller’s.  According to its most recent Investor Fact Sheet, SNPX has a clean capital structure and strong cash position of $31M – which translated to SIX YEARS of operating runway (at current cash burn rate).  Further, according to Finviz, [SNPX]( has a little over $4 in cash per share.  As a refresher, “cash per share” is calculated by taking all the cash the company has on hand and dividing that number by the total shares outstanding. It’s a measure of what’s available to spend on strengthening the company's business, paying down debt, returning money to shareholders, etc.   Another measure of health is to look at the company’s level of debt – so when we check out Finviz again we see that [SNPX](’s also has $0 in DEBT – yes you read that right…no debt!  This is a very fiscally disciplined company; I wish our country’s finances were managed as well as this...   Now, if you back out the cash from the current share price, the market is only valuing the entire core business right now around a measly $20M, or just $3 per share. That is an amazing value, if you ask me.  Bottom line, I think [SNPX]( has a big advantage over other struggling small-cap stocks in the market right now. They don’t need to raise cash anytime soon and can navigate through the turbulence in the market for quite some time.  Also remember, [SNPX]( has a crucial FDA Phase II trial announcement coming up soon (likely before the end of the year). If that is positive, then it should be a huge win for the company and shareholders alike.  These are all reasons why the stock has held up remarkably well in this violent market. In fact, the stock just crossed above the 200-day moving average yesterday. This puts SNPX in rare company right now as only around 26% of all companies are in that bullish territory right now.  Simply put, [SNPX is a gem]( that most investors are overlooking right now.   So, do yourself a favor today. Spend some time getting to understand more about this company and the huge opportunity at hand.  You can get started by reading our in-depth report on SNPX [right here.](  62 Calef Hwy #233 Lee, New Hampshire 03861 United States  Questions or concerns about our products? Email [Support@ragingbull.com](  © Copyright  2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions  FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, neither Sherwood Ventures, LLC (“Sherwood”) nor Ragingbull.com, LLC (“Raging Bull”) can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither Sherwood nor Raging Bull, or any of their owners, employees or independent contractors is currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at. TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. ISSUER-PAID ADVERTISEMENT. Synaptogenix, Inc. (“SNPX” or the “Company”) has paid or will pay Sherwood $30,000 USD per month for three months (the “Initial Term”) in cash, shares of restricted common stock with a value of $150,000, and warrants valued at issuance of $75,000 for marketing services including communicating to the public about the company through Sherwood’s affiliate Raging Bull, among others. This advertisement is part of those issuer-paid marketing services. The contract with SNPX automatically renews for successive one-month periods following the Initial Term (the “Renewal Term”) unless it is terminated by written notice of either party prior to the end of the previous term. During the Renewal Term, SNPX has agreed to pay Sherwood a monthly fee of $30,000 in cash, shares of restricted stock with a value of $50,000 and warrants valued at $25,000. As a result of this advertisement and other marketing efforts, Sherwood and/or Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, Sherwood and Raging Bull, and any of their respective officers, principals, or affiliates (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) hold the securities of SNPX and, as permitted by law, may sell those shares during the course of this marketing arrangement or afterwards. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of SNPX, increased trading volume, and possibly an increased share price of the SNPX’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. [Manage your email subscriptions.](